Frontline Ofatumumab with Hyper-CVAD in CD20+ Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial

Chemoimmunotherapy with hyper-CVAD is an effective frontline regimen for ALL. Ofatumumab potently binds to CD20 with better in vitro activity than rituximab. We hypothesized that addition of ofatumumab (O) to hyper-CVAD may improve outcomes in CD20+ ALL.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research